Allegro Receives FDA Agreement Under SPA for Phase 2b/3 Trial of Risuteganib
12 Apr 2023 //
PR NEWSWIRE
Allegro Announces Presentation of Data Surrounding Dry AMD Pipeline Candidates
10 Feb 2023 //
PR NEWSWIRE
U.S. Phase 2 Study Published in OSLI Retina on Safety of Risuteganib
04 Aug 2021 //
BUSINESSWIRE
William J. Link, PhD, Named Chairman of Allegro Ophthalmics’ Board of Directors
22 Jun 2021 //
BUSINESSWIRE